| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | EX-527 | CTRPv2 | pan-cancer | AAC | -0.0032 | 0.9 |
| mRNA | GSK525762A | CTRPv2 | pan-cancer | AAC | 0.0024 | 0.9 |
| mRNA | AZD0530 | CTRPv2 | pan-cancer | AAC | 0.0029 | 0.9 |
| mRNA | BRD-K42260513 | CTRPv2 | pan-cancer | AAC | -0.0041 | 0.9 |
| mRNA | doxorubicin:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0023 | 0.9 |
| mRNA | Platin | CTRPv2 | pan-cancer | AAC | -0.0025 | 0.9 |
| mRNA | BRD-K19103580 | CTRPv2 | pan-cancer | AAC | 0.0024 | 0.9 |
| mRNA | cimetidine | CTRPv2 | pan-cancer | AAC | 0.0043 | 0.9 |
| mRNA | rigosertib | CTRPv2 | pan-cancer | AAC | -0.0021 | 0.9 |
| mRNA | manumycin A | CTRPv2 | pan-cancer | AAC | 0.002 | 0.9 |